TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05275231

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle interventions (ILIs)
Description: Intensive lifestyle interventions (ILIs) is a group-based programs designed to promote weight loss through a combination of diet, activity, and behavior change, decrease Type 2 Diabetes (T2D) incidence in people with prediabetes and reduced complications among people with T2D.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive lifestyle interventions (ILIs)
Description: Intensive lifestyle interventions (ILIs) is a group-based programs designed to promote weight loss through a combination of diet, activity, and behavior change, decrease Type 2 Diabetes (T2D) incidence in people with prediabetes and reduced complications among people with T2D.
Study: NCT06294717

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive relaxation exercises will be applied.
Description: Progressive relaxation exercises will be not applied.
Study: NCT06227039

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibroacoustic stimulation on
Description: Mechanical stimulus is provided to the patient through a vibroacoustic device via vibration around the neck.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibroacoustic stimulation on
Description: Mechanical stimulus is provided to the patient through a vibroacoustic device via vibration around the neck.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Augmented Reality on
Description: Visual stimulus is provided through augmented reality glasses in the form of a game.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Augmented Reality on
Description: Visual stimulus is provided through augmented reality glasses in the form of a game.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibroacoustic stimulation off
Description: Vibroacoustic device is worn but turned off.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Augmented reality off
Description: Augmented reality glasses are worn but turned off.
Study: NCT04908514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-629
Description: ADX-629 administered orally twice daily (BID) for approximately 12 weeks.
Study: NCT05314231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1720
Description: All enrolled participants will receive a single dose of ALXN1720 on Day 1 followed by a Post-treatment and Follow-up Period (92 days).
Study: NCT05269693

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief Hope Intervention
Description: The BHI consisted of 4 one-on-one sessions: 2 (1 hr) face- to-face sessions, and 2 (30 min) telephone follow-up sessions
Study: NCT04759625

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel biscuit enriched with mushroom powder containing 3g of β-glucans
Description: Daily consumption of a novel biscuit enriched with mushroom powder containing 3g of β-glucans

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo biscuit
Description: Daily consumption of placebo biscuit
Study: NCT05544474

Intervention type: OTHER
Intervention: Delphi questionnaire
Description: An invitation email, including a link to the survey, will be sent to the panel of experts in the field of radical right colectomy. The Delphi questionnaire will be administered via www.surveymonkey.com.~In the first survey, panel members will agree on surgical steps, definition of surgical steps and nomenclature for radical right colectomy In subsequent surveys, panel expert will agree on a common definition, nomenclature and reporting for right colectomy. Multiple rounds will be conducted until consensus is reached. After each round, the study team will calculate the agreement and distribution of responses. Likert responses will be dichotomized with positive values indicating agreement and neutral or negative values indicating disagreement.~For the questions that do not reach a consensus of more than 70% in the first round or need further explanation, additional rounds of the survey may be performed.
Study: NCT06167395

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta Alanine high dose
Description: Subjects should consume 4 intakes of 5 g of beta alanine every 3 hours each day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta Alanine low dose
Description: Subjects should consume 4 intakes of 2,5 g of beta alanine every 3 hours each day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control product
Description: Subjects should consume 4 intakes of 2,5 g of wheat semolina every 3 hours each day.
Study: NCT05317312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MR-107A-02
Description: MR-107A-02 oral tablet
Study: NCT04489199

Intervention type: OTHER
Intervention: Questionnaire and semi-structured interview
Description: questionnaire submitted by telephone 3 months, 6 months, 1 year, 5 years, and 10 years after the stroke/TIA. interview duration 20 to 40 minutes
Study: NCT05207020

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glycemia estimated by exhaled air analyzer
Description: Measurement of volatile compounds in the air exhaled by the volunteer on 3 different MIBs (3 breaths in total) at 7 times: T0, 30min, 1H, 1H30, 2H, 2H30, 3H after test meal

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: The questionnaire focuses on the methods and feelings of the blood glucose self-monitoring that he is currently carrying out, a first feedback on user experience on the operation of the prototype and the collection of his expectations for a future commercial device

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Veinous glycemia
Description: Measurement of the veinous glycemia at 7 times: T0, 30min, 1H, 1H30, 2H, 2H30, 3H after test meal

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Capillary glycemia
Description: 7-step capillary glycemia measurement: T0, 30min, 1H, 1H30, 2H, 2H30, 3H after test meal

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: constitution biological collection
Description: Sampling for storage of serum at 7 times: T0, 30min, 1H, 1H30, 2H, 2H30, 3H after test meal

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Single blood sample before mealtimes for HbA1C molecular analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test meal
Description: taking a test meal before the various blood sugar measurements
Study: NCT05832879

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OUD Telehealth Platform
Description: The platform is intended to encourage engagement in treatment with medications for opioid use disorder (MOUD) through a chat dialogue with users
Study: NCT06583863

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Echinacea Extract
Description: 175 mg of Echinacea extract was provided as an immunlant therapy twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Echinacea Extract
Description: 175 mg of Echinacea extract was provided as an immunlant therapy twice daily.
Study: NCT05317312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MR-107A-02
Description: MR-107A-02 oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral tablet
Study: NCT05575973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride Liposome
Description: Drug: Mitoxantrone hydrochloride liposome (20 mg/m2) will be administered by an intravenous infusion on day 1 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Drug: Rituximab (375 mg/m2) will be administered by an intravenous infusion on day 1 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Drug: Lenalidomide (25 mg) will be taken orally from day 1 to day 8 of each 28-day cycle.
Study: NCT05900674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reteplase Injection
Description: To test the single dose of reteplase (9 U) and Maximum dose (18 U) in acute ischemic stroke patients.
Study: NCT06583863

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MetroNIDAZOLE 500 MG Oral Tablet [Flagyl]
Description: 500 mg of metronidazole was provided as an oral tablets twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MetroNIDAZOLE 500 MG Oral Tablet [Flagyl]
Description: 500 mg of metronidazole was provided as an oral tablets twice daily
Study: NCT05368194

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Isocaloric Unprocessed Diet
Description: Intervention consists of an unprocessed diet meeting the Nordic and Australian Dietary Guidelines for food groups and micronutrients, wherein participants will be supplied with food providing kilocalories (kcal) in accordance with their nutritional needs as calculated based on theSchofield equation based on their weight, activity multiplier, and age at baseline. Almost all food and beverage products provided during this treatment to fall into the category of unprocessed/minimally processed foods and processed culinary ingredients in accordance with the NOVA classification system.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Isocaloric Processed Diet
Description: Intervention consists of a processed diet based on the dietary intake pattern resembling a processed western dietary intake pattern representative of the typical intake pattern of American men aged 19- 50, wherein participants will be supplied with food providing kcals in accordance with their nutritional needs as calculated based on the Schofield equation based on their height, weight, activity multiplier, and age at baseline. Almost all food and beverage products provided during this treatment to fall into the category of processed foods and ultra-processed foods in accordance with the NOVA classification system.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Excess Calorie Unprocessed Diet
Description: Intervention consists of an unprocessed diet meeting the Nordic and Australian Dietary Guidelines for food groups and micronutrients, wherein participants will be supplied with food providing kilocalories (kcal) in accordance with their nutritional needs as calculated based on theSchofield equation based on their weight, activity multiplier, and age at baseline, plus an excess of 500 kcal per day. Almost all food and beverage products provided during this treatment to fall into the category of unprocessed/minimally processed foods and processed culinary ingredients in accordance with the NOVA classification system.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Excess Calorie Processed Diet
Description: Intervention consists of a processed diet based on the dietary intake pattern resembling a processed western dietary intake pattern representative of the typical intake pattern of American men aged 19- 50, wherein participants will be supplied with food providing kcals in accordance with their nutritional needs as calculated based on the Schofield equation based on their height, weight, activity multiplier, and age at baseline, plus an excess of 500 kcal per day. Almost all food and beverage products provided during this treatment to fall into the category of processed foods and ultra-processed foods in accordance with the NOVA classification system.
Study: NCT05932472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin at currently prescribed dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin at currently prescribed dose
Study: NCT04736381

Intervention type: DRUG
Intervention: Belatacept Injection [Nulojix]
Description: Drugs administrated are part of the usual care
Study: NCT05971537

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antibiotic lock
Description: In the intervention arm, in addition to the appropriate IP antibiotics, an antibiotic-lock will be prepared by the same antibiotics. We will follow the suggested data used in hemodialysis catheter for the concentration of different antibiotics to prepare the locking solution . Some commonly used antibiotics for the treatment of PD peritonitis with their suggested concentrations in the antibiotic-lock are quoted as below:~Cefazolin 10mg/mL Ceftazidime 10mg/mL Vancomycin 10mg/mL Gentamicin 5mg/mL Tienam 50mg/mL

Intervention type: DRUG
Group type: OTHER
Intervention: conventional IP antibiotics
Description: In the control arm, appropriate IP antibiotics are to be continued. The dosage and duration of antibiotics will fully follow the recommendation from the latest International Society for Peritoneal Dialysis (ISPD) peritonitis guidelines
Study: NCT05343377

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: circulate free methylated EBV DNA
Description: Accuracy of circulating free methylated EBV DNA in predicting 2-year PFS
Study: NCT05058079

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative Hand Held
Description: Intraoperative hand holding
Study: NCT05897229

Intervention type: OTHER
Intervention: Analysis of costs with patient care during hospitalization
Description: Analysis of direct costs with supplies, medications, diets, laboratory tests and imaging exams, and invasive procedures such as mechanical ventilation, dialysis, and the use of vasoactive drugs.-analysis of costs referring to working hours of physicians, nurses and physical therapists in each unit normalized for the same number of beds.- cost minimization and consequential cost analysis.

Intervention type: OTHER
Intervention: Analysis of costs with patient care during hospitalization
Description: Analysis of direct costs with supplies, medications, diets, laboratory tests and imaging exams, and invasive procedures such as mechanical ventilation, dialysis, and the use of vasoactive drugs.-analysis of costs referring to working hours of physicians, nurses and physical therapists in each unit normalized for the same number of beds.- cost minimization and consequential cost analysis.
Study: NCT05900674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reteplase Injection
Description: To test the single dose of reteplase (9 U) and Maximum dose (18 U) in acute ischemic stroke patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reteplase Injection
Description: To test the single dose of reteplase (9 U) and Maximum dose (18 U) in acute ischemic stroke patients.
Study: NCT05666804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brolucizumab 6mg
Description: Brolucizumab 6mg (intravitreal) Personalized regimen arm: 1\~3 x 4-week loading injections and one 8-week injection, followed by Treat-and-extend (T\&E) regimen up to Week 56

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brolucizumab 6mg
Description: Brolucizumab 6mg(intravitreal) Standard q12w/q8w regimen arm: 3 x 4-week loading injections and disease activity assessment at week 16 followed by q12w/q8w up to Week 56
Study: NCT05954390

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Undenatured beta-glucan solution
Description: The active comparator is a solution containing undenatured beta-glucans

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo comparator is the same solution as the active therapy except it does not contain any undenatured beta-glucans
Study: NCT05897229

Intervention type: OTHER
Intervention: Analysis of costs with patient care during hospitalization
Description: Analysis of direct costs with supplies, medications, diets, laboratory tests and imaging exams, and invasive procedures such as mechanical ventilation, dialysis, and the use of vasoactive drugs.-analysis of costs referring to working hours of physicians, nurses and physical therapists in each unit normalized for the same number of beds.- cost minimization and consequential cost analysis.
Study: NCT05906433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kenalog with bupivacaine Injection
Description: Indications, relevant for this study include Kenalog injection for knee pain from osteoarthritis or inflammatory arthritis. A single injection to a patient who has no known allergies to anesthetic or corticosteroids would be administered during a scheduled clinical visit.
Study: NCT05036876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degludec
Description: Treatment with insulin degludec when compared to insulin glargine U-300 will result in similar blood glucose control in hospitalized patients with type 2 diabetes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine U300
Description: Treatment with insulin glargine U300 when compared to insulin degludec will result in similar blood glucose control in hospitalized patients with type 2 diabetes.
Study: NCT05637931

Intervention type: DIAGNOSTIC_TEST
Intervention: plexinD1
Description: evaluation of the serum level of plexinD1

Intervention type: DIAGNOSTIC_TEST
Intervention: plexinD1
Description: evaluation of the serum level of plexinD1

Intervention type: DIAGNOSTIC_TEST
Intervention: plexinD1
Description: evaluation of the serum level of plexinD1
Study: NCT05906433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kenalog with bupivacaine Injection
Description: Indications, relevant for this study include Kenalog injection for knee pain from osteoarthritis or inflammatory arthritis. A single injection to a patient who has no known allergies to anesthetic or corticosteroids would be administered during a scheduled clinical visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kenalog with bupivacaine Injection
Description: Indications, relevant for this study include Kenalog injection for knee pain from osteoarthritis or inflammatory arthritis. A single injection to a patient who has no known allergies to anesthetic or corticosteroids would be administered during a scheduled clinical visit.
Study: NCT05395325

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: Kinesio tape would be applied (1)over the extensor muscles of the affected hand for facilitating the extension of hand. We will apply the tape from the upper 1/3 length of dorsal side of the forearm and split the tape into five equal bars to the distal interphalangeal joint of each finger along the finger bones. (2) from above the scapula spine to the medial deltoid. (3) from medial border of scapula to anterior deltoid.This intervention would be executed for five days per week for three weeks.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Kinesiotaping
Description: Kinesio tape would be applied (1)over the extensor muscles of the affected hand for facilitating the extension of hand. We will apply the tape from the upper 1/3 length of dorsal side of the forearm and split the tape into five equal bars to the distal interphalangeal joint of each finger along the finger bones. (2) from above the scapula spine to the medial deltoid. (3) from medial border of scapula to anterior deltoid.This intervention would be executed for five days per week for three weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand rehabilitation program
Description: In the thirty-minute hand rehabilitation program, a motor-relearning theory would be implemented into the intervention by teaching the participants how to use their upper limb properly without any compensatory motions. Therefore, for establishing a correct movement pattern, an occupational therapist would provide a hand-guided activity, in which the participants could practice reaching movement as well as hand grasp and release in a more natural way. Besides, the therapist would also help the patients release their muscle tone by stretching the spastic muscles for five minutes before and after this hand rehabilitation period

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Hand rehabilitation program
Description: In the thirty-minute hand rehabilitation program, a motor-relearning theory would be implemented into the intervention by teaching the participants how to use their upper limb properly without any compensatory motions. Therefore, for establishing a correct movement pattern, an occupational therapist would provide a hand-guided activity, in which the participants could practice reaching movement as well as hand grasp and release in a more natural way. Besides, the therapist would also help the patients release their muscle tone by stretching the spastic muscles for five minutes before and after this hand rehabilitation period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Steroid injection
Description: all the steroid injection would be executed by physicians. The 23G needles would be used for the injections. The examiners would be clear and familiar with the protocol, and the injections would be executed for only one time during the study period in experimental group.
Study: NCT06182969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-2575
Description: Take orally once daily (QD) for 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take orally once daily (QD) for 12 weeks.
Study: NCT06149078

Intervention type: DIAGNOSTIC_TEST
Intervention: serum uric acid
Description: to detect the relaton ship of serum uric acid with sevwrity of knee osteoarthritis

Intervention type: DIAGNOSTIC_TEST
Intervention: serum uric acid
Description: to detect the relaton ship of serum uric acid with sevwrity of knee osteoarthritis
Study: NCT05822180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NANOS1 , argent colloïdal ,
Description: orally, during 5 day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NANOS1 , argent colloïdal ,
Description: orally, during 5 day
Study: NCT05765123

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral glucose tolerance test
Description: A drink containing 75g of glucose together with 150mg carbon-13 sodium acetate in 300ml water
Study: NCT06514885

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SDF solution application
Description: silver diamine fluoride (SDF) solution is highly effective in stopping and arresting the progress of decay in dental roots of older adults. The American Dental Association (ADA) has published a guideline based on the up-to-date evidence to support the use of SDF for managing tooth decay. As a non-invasive procedure, application of SDF is simple, quick, painless and non-aerosol generated.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Tonic water
Description: Tonic water will be used as a placebo to mimic the SDF solution.